On August 14, XTALPI declined 5.01% in regular trading, trading at 7.795 HKD/share, with turnover of HKD 255 million.

On the news front, the Life Sciences Tools & Services sector saw broad-based weakness, with Genscript Biotech down 5.93%, Insilico down 5.52%, WuXi AppTec down 3.4%, and WuXi XDC down 3.16%, as funds rotated out of the AI drug discovery segment. The stock had previously rallied over 13% from August 10-11, driven by the launch of its XtalPi Science platform and bullish investment bank coverage, prompting concentrated profit-taking from short-term holders.

Additionally, the company is set to release interim results on August 19, having previously warned of a swing to a net loss of approximately RMB 215 million to 275 million for the first half, compared with a net profit of RMB 82.8 million in the year-ago period. The approaching earnings window intensified cautious market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)